DDInter1141 DDInter649
17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly.
Megestrol acetate {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Enzalutamide
Megestrol acetate {u} (Compound) resembles {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Megestrol acetate {u} (Compound) resembles {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Megestrol acetate {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enzalutamide
Megestrol acetate {u} (Compound) resembles {v} (Compound) Hydrocortisone
Hydrocortisone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Enzalutamide
Megestrol acetate {u} (Compound) resembles {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Enzalutamide
Megestrol acetate {u} (Compound) resembles {v} (Compound) Dydrogesterone
Dydrogesterone {u} (Compound) resembles {v} (Compound) Testosterone
Testosterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Megestrol acetate {u} (Compound) resembles {v} (Compound) Fludrocortisone
Fludrocortisone {u} (Compound) causes {v} (Side Effect) Injury
Injury {u} (Side Effect) is caused by {v} (Compound) Enzalutamide
Megestrol acetate {u} (Compound) resembles {v} (Compound) Dydrogesterone
Dydrogesterone {u} (Compound) resembles {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Megestrol acetate {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Nefazodone
Nefazodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Megestrol acetate (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Enzalutamide (Compound)
Megestrol acetate (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Megestrol acetate (Compound) resembles Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Megestrol acetate (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Megestrol acetate (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Megestrol acetate (Compound) resembles Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Megestrol acetate (Compound) resembles Dydrogesterone (Compound) and Dydrogesterone (Compound) resembles Testosterone (Compound) and Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Megestrol acetate (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone (Compound) causes Injury (Side Effect) and Injury (Side Effect) is caused by Enzalutamide (Compound)
Megestrol acetate (Compound) resembles Dydrogesterone (Compound) and Dydrogesterone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Megestrol acetate (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nefazodone (Compound) and Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide